Welcome to our dedicated page for Abbott Labs SEC filings (Ticker: ABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abbott Laboratories SEC filings document an Illinois healthcare company with common shares listed under ABT and operations in diagnostics, medical devices, nutritionals and branded generic medicines. The filings include Form 8-K reports on operating results, non-GAAP financial measures, material agreements, acquisition-related events, debt financing and amendments to corporate governance documents.
Abbott's proxy and event filings cover shareholder voting matters, board and bylaw governance, executive compensation, capital-structure disclosures and clinical or regulatory disclosures. The filing record also documents the completed Exact Sciences acquisition and the addition of cancer diagnostics to Abbott's broader diagnostic portfolio.
Abbott Laboratories reported that shareholders approved its new 2026 Incentive Stock Program, authorizing up to 140,000,000 common shares for equity-based awards. The plan lets the company grant stock options, restricted stock, restricted stock units, performance awards and other share-based incentives to employees and non-employee directors.
Kevin Conroy was named to Abbott’s Board of Directors, and the board size was increased from twelve to thirteen members effective April 24, 2026. Shareholders also elected the director slate and approved routine governance matters at the annual meeting.
Abbott Laboratories reported first-quarter 2026 results that met its internal expectations and highlighted a major expansion into oncology diagnostics. Net sales were $11.164 billion, up 7.8% year over year, with comparable sales growth of 3.7% after adjusting for foreign exchange, the Exact Sciences acquisition and a structural heart agreement.
GAAP net earnings were $1.077 billion and diluted EPS was $0.61, both down about 19% from a year ago, driven by higher operating costs and acquisition-related charges. Excluding specified items, adjusted net earnings rose to $2.022 billion, and adjusted diluted EPS increased 6% to $1.15.
Medical Devices led growth with reported sales up 13.2%, while Diagnostics rose 6.1% and Established Pharmaceuticals 13.2%; Nutrition declined 6.0% as Abbott reset pricing and volumes. On March 23, 2026, Abbott completed its acquisition of Exact Sciences, creating a new Cancer Diagnostics business built around Cologuard and the Cancerguard multi-cancer screening test.
Abbott now projects full-year 2026 comparable sales growth of 6.5%–7.5% and adjusted diluted EPS of $5.38–$5.58, including $0.20 of dilution from the Exact Sciences deal. It also guided second‑quarter 2026 adjusted diluted EPS to $1.25–$1.31 and declared its 409th consecutive quarterly dividend of $0.63 per share.
ABBOTT LABORATORIES director John G. Stratton received a grant of 382 stock equivalent units as board compensation. The units were credited on the basis of a reference price of $102.67 per unit and are held in a stock equivalent unit account under a grantor trust established by the director.
The stock equivalent units are paid in cash, generally at age 65 or upon retirement from the board, and earn the same return as if the fees were invested in Abbott common shares, including a dividend reinvestment feature. Following this award, Stratton’s balance in the account totals 13,489 stock equivalent units. This is a non‑market, compensation-related acquisition rather than an open-market share purchase or sale.
ABBOTT LABORATORIES director Michael F. Roman received a grant of 367 stock equivalent units on Abbott shares as part of his director compensation. These units are credited to a stock equivalent unit account and are generally paid in cash at about age 65 or upon retirement from the board. Following this award, his balance totals 6,283 stock equivalent units, which earn the same return as if the underlying fees were invested in Abbott common shares, including units acquired through a dividend reinvestment feature.
Gonzalez Patricia Paola reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director Patricia Paola Gonzalez received a grant of 321 Stock Equivalent Units as director compensation. These units were credited on March 31, 2026 at a reference value of $102.67 per unit and track the value of Abbott common shares.
The grant increased her balance to 5,558 Stock Equivalent Units, including amounts accumulated through a dividend reinvestment feature. The units are held in a grantor trust and are generally paid in cash around age 65 or upon retirement from the board, rather than being traded in the open market.
Alpern Robert J reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES director Robert J. Alpern received a grant of 76 stock equivalent units on March 31, 2026 as part of his director compensation. These units are valued at $102.67 per unit and track the return of Abbott common shares.
The units are credited to a stock equivalent unit account in a grantor trust established by the director and are generally paid out in cash at age 65 or upon retirement from the board. After this award and dividend reinvestment activity, his balance totals 10,544 stock equivalent units in this account.
Ahuja Nita reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES director Nita Ahuja received a grant of stock equivalent units as part of her board compensation. On this Form 4, she was awarded 102 stock equivalent units, each priced at $102.67, credited to a stock equivalent unit account.
The footnote explains these director fees are credited to the account and generally paid in cash at age 65 or upon retirement from the board, earning the same return as if invested in Abbott common shares. Following this grant, her reported balance in this account is 102 stock equivalent units.
Abbott Laboratories received an amended Schedule 13G/A from The Vanguard Group stating that, following an internal realignment, Vanguard and certain subsidiaries will report beneficial ownership separately. The filing lists Amount beneficially owned: 0 shares and Percent of class: 0% with an effective date shown as 03/13/2026.
ORVILLE JACOB A reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES Senior Vice President Orville Jacob A received a grant of 13,255 common shares as a restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 2-year term, with one-half vesting in any one year beginning on March 23, 2027.
Following this grant, he directly holds 50,493 common shares. The award includes the right to have shares withheld to cover tax obligations rather than paying taxes in cash.